Low‐dose anti‐hepatitis B immunoglobulin regimen as prophylaxis for hepatitis B recurrence after liver transplantation

2019 ◽  
Vol 21 (6) ◽  
Author(s):  
Wei‐Chen Lee ◽  
Hong‐Shiue Chou ◽  
Tsung‐Han Wu ◽  
Chih‐Hsien Cheng ◽  
Chen‐Fang Lee ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
Low Dose ◽  
Hepatitis B Immunoglobulin

scholarly journals One Year of Hepatitis B Immunoglobulin Plus Tenofovir Therapy is Safe and Effective in Preventing Recurrent Hepatitis B Infection Post-Liver Transplantation

2014 ◽  
Vol 28 (1) ◽  
pp. 41-44 ◽  
Author(s):  
Tomohiro Tanaka ◽  
Eberhard L Renner ◽  
Nazia Selzner ◽  
George Therapondos ◽  
Leslie B Lilly
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
Low Dose ◽  
Cost Effective ◽  
Hbv Infection ◽  
Recurrent Hepatitis ◽  
Hepatitis B Immunoglobulin ◽  
One Year ◽  
Related Liver Disease

BACKGROUND: Hepatitis B immunoglobulin (HBIG) given in combination with a nucleos(t)ide analogue has reduced the rate of recurrent hepatitis B virus (HBV) infection following liver transplantation (LT); however, the most effective protocol remains unclear.OBJECTIVE: To evaluate the use of tenofovir disoproxil fumarate (TDF) in combination with one year of low-dose HBIG.METHODS: Twenty-four adults who underwent LT for HBV-related liver disease at the University Health Network (Toronto, Ontario) and received TDF (± lamivudine) and one year of HBIG to prevent recurrent HBV infection from June 2005 to June 2011 were evaluated.RESULTS: The median length of follow-up post-LT was 29.1 months. Three patients died during the follow-up period. Patient survival was 100% and 84.1% at one and five years, respectively. None of the patients developed recurrent HBV infection. No significant adverse event was observed due to TDF administration; renal function pre- and post-LT were also acceptably preserved.CONCLUSION: The present study demonstrated that a short, finite course of low-dose HBIG combined with maintenance of long-term TDF staring before LT is cost-effective and safe. However, further prospective study involving a larger patient cohort with a longer followup period is required to confirm the results.

Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation

2007 ◽  
Vol 132 (3) ◽  
pp. 931-937 ◽  
Author(s):  
Edward J. Gane ◽  
Peter W. Angus ◽  
Simone Strasser ◽  
Darrell H.G. Crawford ◽  
John Ring ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
Low Dose ◽  
Recurrent Hepatitis ◽  
Hepatitis B Immunoglobulin

scholarly journals COMBINATION OF LOW DOSE HEPATITIS B IMMUNOGLOBULIN AND LAMIVUDINE FOR HEPATITIS B PROPHYLAXIS AFTER LIVER TRANSPLANTATION

2010 ◽  
Vol 90 ◽  
pp. 856
Author(s):  
G. Moray ◽  
S. Aktas ◽  
Y. Ekici ◽  
H. Karakayali ◽  
U. Yilmaz ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
Low Dose ◽  
Hepatitis B Immunoglobulin

Prophylactic Use of Low-Dose, On-Demand, Intramuscular Hepatitis B Immunoglobulin and Lamivudine After Liver Transplantation

2006 ◽  
Vol 38 (2) ◽  
pp. 579-583 ◽  
Author(s):  
S. Karademir ◽  
H. Astarcıoğlu ◽  
M. Akarsu ◽  
S. Özkardes̨ler ◽  
D. Özzeybek ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis B ◽  
Low Dose ◽  
On Demand ◽  
Hepatitis B Immunoglobulin ◽  
Prophylactic Use
Sign in / Sign up

Export Citation Format

Share Document